A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis

Bibliographic Details
Main Authors:	Bertamino M, Filocamo G, Consolaro A, Palmisani E, Bracciolini G, Suffia C, Muratore V, Ruperto N, Martini A, Ravelli A
Format:	Article
Language:	English
Published:	BMC 2011-09-01
Series:	Pediatric Rheumatology Online Journal

Similar Items

Agreement between objective and subjective definitions of inactive disease, remission and minimal disease activity in juvenile idiopathic arthritis
by: Davì S, et al.
Published: (2011-09-01)

A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
by: Cecilia Bava, et al.
Published: (2019-07-01)

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
by: Davì S, et al.
Published: (2008-09-01)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
by: Consolaro A, et al.
Published: (2008-09-01)

Children with juvenile idiopathic arthritis currently followed in a tertiary care setting have a better psychosocial well-being than healthy peers
by: Suffia C, et al.
Published: (2011-09-01)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)
by: Filocamo G, et al.
Published: (2008-09-01)

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
by: Meiorin S, et al.
Published: (2008-09-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

Do parent's global rating of well-being and disease activity of children with juvenile idiopathic arthritis yield different information?
by: Ullmann N, et al.
Published: (2008-09-01)

A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
by: Martini A, et al.
Published: (2011-09-01)

Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
by: Espada Graciela, et al.
Published: (2011-09-01)

Impaired Muscular Fat Metabolism in Juvenile Idiopathic Arthritis in Inactive Disease
by: Emmanuelle Rochette, et al.
Published: (2019-05-01)

Comparison of physician's, parent's and patient's global ratings made on linear or 21-circle visual analogue scales (VAS) in juvenile idiopathic arthritis (JIA)
by: Dalprà S, et al.
Published: (2008-09-01)

Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD)
by: Palmisani E, et al.
Published: (2008-09-01)

Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
by: Gabriella Giancane, et al.
Published: (2019-07-01)

Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis
by: Buoncompagni Antonella, et al.
Published: (2007-12-01)

Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
by: Magnani A, et al.
Published: (2008-09-01)

Current Treatments for Juvenile Idiopathic Arthritis
by: Alberto eMartini, et al.
Published: (2011-10-01)

Consenso em reumatologia pediátrica: parte I - definição dos critérios de doença inativa e remissão em artrite idiopática juvenil/artrite reumatóide juvenil Consensus in pediatric rheumatology: part I - criteria definition of inactive disease and remission in juvenile idiopathic arthritis / juvenile rheumatoid arthritis
by: Claudia Machado, et al.
Published: (2005-02-01)

Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients
by: Solari N, et al.
Published: (2008-09-01)

Inactive disease and remission rates after intraarticular steroids as initial therapy for juvenile idiopathic arhtritis (JIA)
by: Brito RG, et al.
Published: (2011-09-01)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
by: M. Bielak, et al.
Published: (2018-04-01)

Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
by: Rachel A. Brown, et al.
Published: (2018-12-01)

Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)
by: Lattanzi B, et al.
Published: (2008-09-01)

Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study
by: Patricia Patricia Aires, et al.
Published: (2021-04-01)

Pain intensity in patients with juvenile idiopathic arthritis with respect to the level of their activity and disease acceptance
by: Grażyna Cepuch, et al.
Published: (2014-11-01)

Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study
by: Palmisani E, et al.
Published: (2011-09-01)

Strategies for the withdrawal of classic and biological DMARD in clinically inactive patients with juvenile idiopathic arthritis
by: Soraia Azevedo Azevedo, et al.
Published: (2020-07-01)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
by: Cron Randy Q, et al.
Published: (2011-09-01)

Kienbock’s disease and juvenile idiopathic arthritis
by: Nicholas M Desy, et al.
Published: (2020-08-01)

Hospital clinical pathways for children affected by juvenile idiopathic arthritis
by: L. Cavazzana, et al.
Published: (2018-11-01)

ABATACEPT: A NEW CHOICE FOR CHILDREN WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
by: N. Ruperto
Published: (2010-03-01)

ABATACEPT: A NEW CHOICE FOR CHILDREN WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
by: N. Ruperto
Published: (2010-01-01)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
by: Verazza S, et al.
Published: (2008-09-01)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
by: Rossi L, et al.
Published: (2008-09-01)

Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study
by: Consolaro Alessandro, et al.
Published: (2012-11-01)

Obesity and disease activity in juvenile idiopathic arthritis
by: Pelajo Christina F, et al.
Published: (2012-01-01)

Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra
by: Martini Alberto, et al.
Published: (2011-09-01)

Sleep and its relationship to health-related quality of life in children and adolescents with inactive juvenile idiopathic arthritis
by: Georgia Tsipoura, et al.
Published: (2018-07-01)

Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients
by: Pamela Vernocchi, et al.
Published: (2020-10-01)